There were 524 press releases posted in the last 24 hours and 155,953 in the last 365 days.

Celiac Disease Therapeutic Pipeline Market Review, H2 2016


Celiac Disease Treatment Pipeline Review H2 2016

PUNE, INDIA, October 14, 2016 / -- This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Get Sample Report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Celiac Disease Overview 9
Therapeutics Development 10
Pipeline Products for Celiac Disease - Overview 10
Pipeline Products for Celiac Disease - Comparative Analysis 11
Celiac Disease - Therapeutics under Development by Companies 12
Celiac Disease - Therapeutics under Investigation by Universities/Institutes 13
Celiac Disease - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Celiac Disease - Products under Development by Companies 17
Celiac Disease - Products under Investigation by Universities/Institutes 18
Celiac Disease - Companies Involved in Therapeutics Development 19
Alba Therapeutics Corporation 19
Alvine Pharmaceuticals, Inc. 20
Amgen Inc. 21
Amyra Biotech AG 22
Avaxia Biologics, Inc. 23
Calypso Biotech SA 24
enGene, Inc 25
Glenmark Pharmaceuticals Ltd. 26
ImmusanT, Inc. 27
Intrexon Corporation 28
Provid Pharmaceuticals, Inc. 29
Selecta Biosciences, Inc. 30
Sitari Pharmaceuticals, Inc. 31
Zedira GmbH 32
Celiac Disease - Therapeutics Assessment 33
Assessment by Monotherapy Products 33

Access Report @

Follow Us:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here